Multiple Sclerosis Trial, Recruiting (NCT05809986)

Multiple Sclerosis Trial, Recruiting NCT05809986 Sponsor: Novartis Pharmaceuticals Condition: Multiple Sclerosis

Printed from Voxsanity (voxsanity.com.au) — NCT05809986 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Multiple Sclerosis

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People aged 18 years or older.
People who are willing and able to give written consent before the study begins.
People who are willing and able to complete study assessments, including patient questionnaires, throughout the study.
People who had a diagnosis of relapsing multiple sclerosis (a type of MS that involves flare-ups) confirmed using established diagnostic guidelines before starting the medication Ofatumumab (brand name Kesimpta®).
People whose treatment with Ofatumumab fits within the approved Portuguese prescribing guidelines for this medication — specifically, adult patients with relapsing MS who have signs of active disease based on symptoms or brain/spinal imaging.
People who either started Ofatumumab within the 12 months before joining the study, or who are beginning Ofatumumab at the time of joining.

Who may not be able to join:

People who have used or are using an experimental (investigational) drug during the study, between starting Ofatumumab and joining the study, or within a certain period before starting Ofatumumab (confirm with trial site for exact timeframes).
People who, before starting Ofatumumab, were treated with certain powerful MS medications, including Ocrelizumab, Natalizumab, Mitoxantrone, Rituximab, or Alemtuzumab.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 26 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Novartis Pharmaceuticals, Novartis Pharmaceuticals

Phone: +41613241111

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT05809986

Sponsor: Novartis Pharmaceuticals

Phase: Not Applicable

Status: Recruiting

Condition: Multiple Sclerosis

Trial contact: +41613241111

More information: https://clinicaltrials.gov/study/NCT05809986

Eligibility summary (AI generated)

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People aged 18 years or older.
People who are willing and able to give written consent before the study begins.
People who are willing and able to complete study assessments, including patient questionnaires, throughout the study.
People who had a diagnosis of relapsing multiple sclerosis (a type of MS that involves flare-ups) confirmed using established diagnostic guidelines before starting the medication Ofatumumab (brand name Kesimpta®).
People whose treatment with Ofatumumab fits within the approved Portuguese prescribing guidelines for this medication — specifically, adult patients with relapsing MS who have signs of active disease based on symptoms or brain/spinal imaging.
People who either started Ofatumumab within the 12 months before joining the study, or who are beginning Ofatumumab at the time of joining.

Who may not be able to join:

People who have used or are using an experimental (investigational) drug during the study, between starting Ofatumumab and joining the study, or within a certain period before starting Ofatumumab (confirm with trial site for exact timeframes).
People who, before starting Ofatumumab, were treated with certain powerful MS medications, including Ocrelizumab, Natalizumab, Mitoxantrone, Rituximab, or Alemtuzumab.

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 26 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Novartis Pharmaceuticals

Registry

ClinicalTrials.gov

Start date

27 November 2023

Est. completion

31 December 2026

Where this trial is recruiting

🇵🇹 Portugal

Primary endpoints

Proportion of patients demonstrating NEDA-3

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 26 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov